Nykode Therapeutics AS (CHIX:NYKDO) EBIT: kr-181.17 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:NYKDO Nykode Therapeutics AS CHIX:NYKDO
48 GF Score
Price kr18.69
GF Value kr42.15
! 1 Warning Sign
View Full Analysis

What is Nykode Therapeutics AS EBIT?

Nykode Therapeutics AS CHIX:NYKDO 48 EBIT is kr-181.17 Mil as of Mar. 2026. GuruFocus rates CHIX:NYKDO with a GF Score™ of 48/100 and a GF Value™ of kr42.15. The stock has 1 warning sign investors should review.

Nykode Therapeutics AS's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr-39.44 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-181.17 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nykode Therapeutics AS's annualized ROC % for the quarter that ended in Mar. 2026 was -61.15%. Nykode Therapeutics AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -295.77%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nykode Therapeutics AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -43.24%.

Nykode Therapeutics AS  (CHIX:NYKDo) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nykode Therapeutics AS's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-252.516 * ( 1 - 0% )/( (432.333 + 393.55)/ 2 )
=-252.516/412.9415
=-61.15 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1010.235 - 14.958 - ( 605.009 - max(0, 62.582 - 625.526+605.009))
=432.333

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=906.633 - 21.007 - ( 495.312 - max(0, 42.189 - 534.265+495.312))
=393.55

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Nykode Therapeutics AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-157.744/( ( (57.448 + max(-34.191, 0)) + (49.22 + max(-29.614, 0)) )/ 2 )
=-157.744/( ( 57.448 + 49.22 )/ 2 )
=-157.744/53.334
=-295.77 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 15.757) - (14.958 + 0 + 34.99)
=-34.191

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (21.007 + 0 + 8.607)
=-29.614

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nykode Therapeutics AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-181.172/418.964
=-43.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS EBIT Related Terms

Nykode Therapeutics AS EBIT Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS EBIT Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only -98.68 -501.34 -462.72 -508.57 -177.61

Nykode Therapeutics AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.98 -11.53 -49.18 -81.03 -39.44

CHIX:NYKDO vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Nykode Therapeutics AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nykode Therapeutics AS EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nykode Therapeutics AS's EV-to-EBIT falls into.


CHIX:NYKDO
48GF Score
Nykode Therapeutics AS CHIX:NYKDO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-181.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-181.17 Mil mean?
Nykode Therapeutics AS (CHIX:NYKDO) has a EBIT of kr-181.17 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nykode Therapeutics AS.
Is Nykode Therapeutics AS's EBIT too high?
Nykode Therapeutics AS's current EBIT is kr-181.17 Mil. Overall, Nykode Therapeutics AS has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's EBIT compare to VRTX and REGN?
Nykode Therapeutics AS's EBIT of kr-181.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Nykode Therapeutics AS. Nykode Therapeutics AS's current EBIT is kr-181.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Nykode Therapeutics AS (CHIX:NYKDO) has a current EBIT of kr-181.17 Mil. The stock's GF Value™ is kr42.15, compared to a current price of kr18.69 — trading 55.7% below its estimated fair value. The current EBIT is kr-181.17 Mil. Nykode Therapeutics AS's overall GF Score™ is 48/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Nykode Therapeutics AS (CHIX:NYKDO), the current EBIT is kr-181.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (CHIX:NYKDO) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of kr18.69 is trading 55.7% below its estimated GF Value™ of kr42.15.

Key valuation signals for CHIX:NYKDO:

  • EBIT: kr-181.17 Mil
  • GF Value™: kr42.15 vs. price of kr18.69 (55.7% below fair value)
  • GF Score™: 48/100 with 1 warning sign

No single metric tells the full story. See the CHIX:NYKDO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
48GF Score

Get the complete analysis for CHIX:NYKDO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr18.69
Price
kr42.15
GF Value